178 related articles for article (PubMed ID: 33092566)
41. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
[TBL] [Abstract][Full Text] [Related]
42. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
43. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
44. Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review.
Belleudi V; Marchetti F; Finocchietti M; Davoli M; Addis A
BMJ Paediatr Open; 2021; 5(1):e000985. PubMed ID: 33748434
[TBL] [Abstract][Full Text] [Related]
45. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
[TBL] [Abstract][Full Text] [Related]
46. Administration of Palivizumab in the NICU.
Vendetti N; Gerber JS; Sammons JS; Fisher BT; Zaoutis TE; Coffin SE
Hosp Pediatr; 2016 Jun; 6(6):354-8. PubMed ID: 27164941
[TBL] [Abstract][Full Text] [Related]
47. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
[TBL] [Abstract][Full Text] [Related]
48. Balanced on the Biggest Wave: Nirsevimab for Newborns.
McPherson C; Lockowitz CR; Newland JG
Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
[TBL] [Abstract][Full Text] [Related]
49. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
50. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
51. An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study.
Servadio M; Finocchietti M; Vassallo C; Cipelli R; Heiman F; Di Lucchio G; Oresta B; Addis A; Belleudi V
Ital J Pediatr; 2024 Mar; 50(1):56. PubMed ID: 38528568
[TBL] [Abstract][Full Text] [Related]
52. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
[TBL] [Abstract][Full Text] [Related]
53. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ
Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
[TBL] [Abstract][Full Text] [Related]
54. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of palivizumab in New Zealand.
Vogel AM; McKinlay MJ; Ashton T; Lennon DR; Harding JE; Pinnock R; Graham D; Grimwood K; Pattemore PK; Schousboe M
J Paediatr Child Health; 2002 Aug; 38(4):352-7. PubMed ID: 12173995
[TBL] [Abstract][Full Text] [Related]
56. Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study.
Lin YJ; Chung CH; Chi H; Lin CH
Pediatr Res; 2019 Nov; 86(5):628-634. PubMed ID: 31261371
[TBL] [Abstract][Full Text] [Related]
57. Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant.
Acero-Bedoya S; Wozniak PS; Sánchez PJ; Ramilo O; Mejias A
Am J Perinatol; 2019 Jul; 36(S 02):S63-S67. PubMed ID: 31238362
[TBL] [Abstract][Full Text] [Related]
58. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
59. Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab.
Faldella G; Alessandroni R; Aquilano G; Vandini S; Lanari M; Silvestri M; Pistorio A; Rossi GA
J Chemother; 2010 Feb; 22(1):30-5. PubMed ID: 20227990
[TBL] [Abstract][Full Text] [Related]
60. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
